A
Adaptive Biotechnologies Corporation (ADPT)
NMS – Real vaqt narxi. Valyuta: USD
13.63
+0.09 (0.66%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
13.63
+0.09 (0.66%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Adaptive Biotechnologies Corporation, tijorat bosqichidagi kompaniya, turli kasalliklarni tashxislash va davolash uchun immunitet tibbiyoti platformasini ishlab chiqadi. Kompaniya immunitet tizimini tushunish uchun klinik immunomika ma'lumotlarini yaratish uchun patentlangan kimyo, hisoblash biologiyasi va mashinani o'rganish to'plamini birlashtirgan immunosekvenlash platformasini taklif etadi. U bemorning davolanish paytida va undan keyin uning tanasida mavjud bo'lgan saraton hujayralari sonini aniqlaydigan va kuzatadigan clonoSEQ diagnostika testini taqdim etadi, bu Minimal Qoldiq Kasallik (MRD) deb nomlanadi. Kompaniya hayot haqidagi fanlar tadqiqotlari, klinik diagnostika va dori-darmonlarni kashf qilish dasturlari uchun mahsulot va xizmatlarni taklif etadi. Kompaniya ilgari Adaptive TCR Corporation nomi bilan tanilgan va 2011 yil dekabr oyida Adaptive Biotechnologies Corporation nomini o'zgartirgan. Adaptive Biotechnologies Corporation 2009 yilda ro'yxatga olingan va Sietl, Vashingtonda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Harlan S. Robins Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Sharon Benzeno Ph.D. | Chief Commercial Officer of Immune Medicine |
| Mr. Chad M. Robins M.B.A. | Co-Founder, CEO & Chairman |
| Mr. Christopher Carlson Ph.D. | Founder |
| Mr. Francis T. Lo | Chief People Officer |
| Mr. Kyle Piskel | VP, CFO & Principal Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 8-K | adpt-20260505.htm |
| 2026-05-05 | 10-Q | adpt-20260331.htm |
| 2026-04-24 | DEFA14A | adpt_defa_14a.htm |
| 2026-04-24 | DEF 14A | adpt-20260423.htm |
| 2026-02-27 | S-8 | d105844ds8.htm |
| 2026-02-26 | 10-K | adpt-20251231.htm |
| 2026-02-05 | 8-K | adpt-20260205.htm |
| 2026-01-12 | 8-K | d29941d8k.htm |
| 2025-12-30 | 8-K | d81101d8k.htm |
| 2025-11-05 | 8-K | adpt-20251105.htm |
| Ms. Clarice McCauley | Head of Legal, Corporate Secretary, VP & Chief Compliance Officer |
| Ms. Julie Rubinstein | President & COO |
| Ms. Karina Calzadilla | Vice President of Investor Relations |
| Ms. Susan Bobulsky | Chief Commercial Officer of MRD |